Literature DB >> 24383475

Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.

Charles E Schiaffo1, Ce Shi, Zhengming Xiong, Michael Olin, John R Ohlfest, Courtney C Aldrich, David M Ferguson.   

Abstract

Toll-like receptors 7 and 8 (TLRs) have emerged as key targets in the design of small molecule adjuvants and stimulants for use in immunotherapies. This study examines the structure-activity relationship of a series of C2- and N1-substituted C7-methoxycarbonylimidazoquinolines to gain insight to the structural basis to TLR-7 and -8 selective activity. The analysis is further applied to evaluate the induction of multiple cytokines, including IL-10, IL-12, IL-1β, TNF-α, IFN-α, and IFN-γ, using murine BMDCs and human PBMCs. The results show TLR-7/8 activity is correlated to the C2-alkyl chain length, with peak activity occurring for the butyl (TLR-7) and pentyl (TLR-8) derivatives. A similar SAR is identified in the production of IL-1β, IL-12, and IFN-γ, which are shown to depend on both the C2-alkyl chain length and substitution to the N1-position. The compounds were also potent stimulators of IFN-α and IL-10 production but with less pronounced structure-based correlations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24383475     DOI: 10.1021/jm4004957

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Structure-Activity Relationship Studies of Pyrimido[5,4-b]indoles as Selective Toll-Like Receptor 4 Ligands.

Authors:  Michael Chan; Yuhei Kakitsubata; Tomoko Hayashi; Alast Ahmadi; Shiyin Yao; Nikunj M Shukla; Shin-Ya Oyama; Akihito Baba; Brandon Nguyen; Maripat Corr; Yasuo Suda; Dennis A Carson; Howard B Cottam; Masahiro Wakao
Journal:  J Med Chem       Date:  2017-11-03       Impact factor: 7.446

2.  Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists.

Authors:  Sashi Debnath; Guiyang Hao; Bing Guan; Pawan Thapa; Justin Hao; Hans Hammers; Xiankai Sun
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

3.  Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.

Authors:  Peter Larson; Tamara A Kucaba; Zhengming Xiong; Michael Olin; Thomas S Griffith; David M Ferguson
Journal:  ACS Med Chem Lett       Date:  2017-10-16       Impact factor: 4.345

4.  Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.

Authors:  Jordan R Hunt; Peter A Kleindl; K Ryan Moulder; Thomas E Prisinzano; M Laird Forrest
Journal:  Bioorg Med Chem Lett       Date:  2019-11-09       Impact factor: 2.823

5.  Association between Toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma.

Authors:  Irene Russo; Camilla Cona; Andrea Saponeri; Franco Bassetto; Vincenzo Baldo; Mauro Alaibac
Journal:  Biomed Rep       Date:  2016-02-15

6.  Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.

Authors:  Alex C D Salyer; Giuseppe Caruso; Karishma K Khetani; Lauren M Fox; Subbalakshmi S Malladi; Sunil A David
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

Review 7.  Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

Authors:  Deepender Kaushik; Arshpreet Kaur; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2021-05-14

8.  Tetrasubstituted imidazoles as incognito Toll-like receptor 8 a(nta)gonists.

Authors:  Yi Yang; Adam Csakai; Shuangshuang Jiang; Christina Smith; Hiromi Tanji; Jian Huang; Torey Jones; Kentaro Sakaniwa; Lindsey Broadwell; Chengrui Shi; Subada Soti; Umeharu Ohto; Yaohui Fang; Shu Shen; Fei Deng; Toshiyuki Shimizu; Hang Yin
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 14.919

Review 9.  Virtual Screening Approaches towards the Discovery of Toll-Like Receptor Modulators.

Authors:  Lucía Pérez-Regidor; Malik Zarioh; Laura Ortega; Sonsoles Martín-Santamaría
Journal:  Int J Mol Sci       Date:  2016-09-09       Impact factor: 5.923

10.  BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant.

Authors:  Deepender Kaushik; Simran Dhingra; Madhuri T Patil; Sakshi Piplani; Varun Khanna; Yoshikazu Honda-Okubo; Lei Li; Johnson Fung; Isaac G Sakala; Deepak B Salunke; Nikolai Petrovsky
Journal:  Hum Vaccin Immunother       Date:  2020-04-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.